Literature DB >> 21177803

Acquisition of host-derived CD40L by HIV-1 in vivo and its functional consequences in the B-cell compartment.

Michaël Imbeault1, Michel Ouellet, Katia Giguère, Jonathan Bertin, Dave Bélanger, Geneviève Martin, Michel J Tremblay.   

Abstract

Aberrant activation of the B-cell compartment and hypergammaglobulinemia were among the first recognized characteristics of HIV-1-infected patients in the early 1980s. It has been demonstrated previously that HIV-1 particles acquire the costimulatory molecule CD40L when budding from activated CD4(+) T cells. In this paper, we confirmed first that CD40L-bearing virions are detected in the plasma from untreated HIV-1-infected individuals. To define the biological functions of virus-associated CD40L and fully characterize its influence on the activation state of B cells, we conducted a large-scale gene expression analysis using microarray technology on B cells isolated from human tonsillar tissue. Comparative analyses of gene expression profiles revealed that CD40L-bearing virions induce a highly similar response to the one observed in samples treated with a CD40 agonist, indicating that virions bearing CD40L can efficiently activate B cells. Among modulated genes, many cytokines/chemokines (CCL17, CCL22), surface molecules (CD23, CD80, ICAM-1), members of the TNF superfamily (FAS, A20, TNIP1, CD40, lymphotoxin alpha, lymphotoxin beta), transcription factors and associated proteins (NFKB1, NFKBIA, NFKBIE), second messengers involved in CD40 signaling (TRAF1, TRAF3, MAP2K1, phosphatidylinositol 3-kinase), and the activation-induced cytidine deaminase (AID) were identified. Moreover, we show that soluble factors induced upon the exposure of B cells to CD40L-bearing virions can exert chemoattractant properties toward CD4(+) T cells. We thus propose that a positive feedback loop involving CD40L-bearing HIV-1 particles issued from CD4(+) T cells productively infected with HIV-1 play a role in the virus-induced dysfunction of humoral immunity by chronically activating B cells through sustained CD40 signaling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21177803      PMCID: PMC3067784          DOI: 10.1128/JVI.01993-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

Review 1.  Rearrangement/hypermutation/gene conversion: when, where and why?

Authors:  J C Weill; C A Reynaud
Journal:  Immunol Today       Date:  1996-02

Review 2.  Distinctive characteristics of germinal center B cells.

Authors:  S Han; B Zheng; Y Takahashi; G Kelsoe
Journal:  Semin Immunol       Date:  1997-08       Impact factor: 11.130

3.  CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines.

Authors:  R S Kornbluth; K Kee; D D Richman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-28       Impact factor: 11.205

Review 4.  Lymphotoxin-alpha-deficient and TNF receptor-I-deficient mice define developmental and functional characteristics of germinal centers.

Authors:  M Matsumoto; Y X Fu; H Molina; D D Chaplin
Journal:  Immunol Rev       Date:  1997-04       Impact factor: 12.988

Review 5.  Functions of CD40 and its ligand, gp39 (CD40L).

Authors:  J D Laman; E Claassen; R J Noelle
Journal:  Crit Rev Immunol       Date:  1996       Impact factor: 2.214

6.  CD40 ligand (CD154) incorporated into HIV virions induces activation-induced cytidine deaminase (AID) expression in human B lymphocytes.

Authors:  Marta Epeldegui; Dharma R Thapa; Justin De la Cruz; Scott Kitchen; Jerome A Zack; Otoniel Martínez-Maza
Journal:  PLoS One       Date:  2010-07-06       Impact factor: 3.240

7.  Possible role of interleukin-10 (IL-10) and CD40 ligand expression in the pathogenesis of hypergammaglobulinemia in human immunodeficiency virus infection: modulation of IL-10 and Ig production after intravenous Ig infusion.

Authors:  F Müller; P Aukrust; I Nordoy; S S Froland
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

8.  Tumor necrosis factor beta and soluble APO-1/Fas independently predict progression to AIDS in HIV-seropositive patients.

Authors:  F J Medrano; M Leal; D Arienti; C Rey; A Zagliani; Y Torres; A Sanchez-Quijano; E Lissen; M Clerici
Journal:  AIDS Res Hum Retroviruses       Date:  1998-07-01       Impact factor: 2.205

9.  The amount of host HLA-DR proteins acquired by HIV-1 is virus strain- and cell type-specific.

Authors:  R Cantin; J F Fortin; M Tremblay
Journal:  Virology       Date:  1996-04-15       Impact factor: 3.616

Review 10.  Modulation of life and death by the TNF receptor superfamily.

Authors:  S J Baker; E P Reddy
Journal:  Oncogene       Date:  1998-12-24       Impact factor: 9.867

View more
  25 in total

1.  Dysregulated B-cell TLR2 expression and elevated regulatory B-cell frequency precede the diagnosis of AIDS-related non-Hodgkin lymphoma.

Authors:  Basile Siewe; Joey T Pham; Mardge Cohen; Nancy A Hessol; Alexandra Levine; Otoniel Martinez-Maza; Alan Landay
Journal:  AIDS       Date:  2015-08-24       Impact factor: 4.177

2.  Regulatory B cell frequency correlates with markers of HIV disease progression and attenuates anti-HIV CD8⁺ T cell function in vitro.

Authors:  Basile Siewe; Jack T Stapleton; Jeffrey Martinson; Ali Keshavarzian; Nazia Kazmi; Patricia M Demarais; Audrey L French; Alan Landay
Journal:  J Leukoc Biol       Date:  2013-02-22       Impact factor: 4.962

3.  Immunoglobulin VH gene diversity and somatic hypermutation during SIV infection of rhesus macaques.

Authors:  Kejun Guo; Kalani Halemano; Kimberly Schmitt; Miki Katuwal; Yaqiong Wang; Michael S Harper; Karl J Heilman; Takeo Kuwata; Edward B Stephens; Mario L Santiago
Journal:  Immunogenetics       Date:  2015-05-21       Impact factor: 2.846

4.  Immune Activation: Contribution to AIDS-Associated Non-Hodgkin Lymphoma.

Authors:  Marta Epeldegui; Otoniel Martínez-Maza
Journal:  For Immunopathol Dis Therap       Date:  2015

5.  Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection.

Authors:  M-A Jenabian; M Patel; I Kema; K Vyboh; C Kanagaratham; D Radzioch; P Thébault; R Lapointe; N Gilmore; P Ancuta; C Tremblay; J-P Routy
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

6.  B-cell activation induced microRNA-21 is elevated in circulating B cells preceding the diagnosis of AIDS-related non-Hodgkin lymphomas.

Authors:  Dharma R Thapa; Kishor Bhatia; Jay H Bream; Gypsyamber DʼSouza; Charles R Rinaldo; Steven Wolinsky; Roger Detels; Otoniel Martínez-Maza
Journal:  AIDS       Date:  2012-06-01       Impact factor: 4.177

7.  Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial).

Authors:  Marta Epeldegui; Jeannette Y Lee; Anna C Martínez; Daniel P Widney; Larry I Magpantay; Deborah Regidor; Ronald Mitsuyasu; Joseph A Sparano; Richard F Ambinder; Otoniel Martínez-Maza
Journal:  Clin Cancer Res       Date:  2015-09-17       Impact factor: 12.531

Review 8.  A lymphomagenic role for HIV beyond immune suppression?

Authors:  Riccardo Dolcetti; Annunziata Gloghini; Arnaldo Caruso; Antonino Carbone
Journal:  Blood       Date:  2016-01-14       Impact factor: 22.113

9.  TLR2-activated B cells are phenotypically similar to the abnormal circulating B cells seen preceding the diagnosis of AIDS-related NHL diagnosis.

Authors:  Yu Guo; Basile Siewe; Marta Epeldegui; Roger Detels; Alan L Landay; Otoniel Martínez-Maza
Journal:  J Acquir Immune Defic Syndr       Date:  2013-10-01       Impact factor: 3.731

10.  Serum levels of cytokines and biomarkers for inflammation and immune activation, and HIV-associated non-Hodgkin B-cell lymphoma risk.

Authors:  Elena Vendrame; Shehnaz K Hussain; Elizabeth Crabb Breen; Larry I Magpantay; Daniel P Widney; Lisa P Jacobson; Daina Variakojis; Emilee R Knowlton; Jay H Bream; Richard F Ambinder; Roger Detels; Otoniel Martínez-Maza
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-11-12       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.